Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Zagotenemab (Primary) ; Florbetapir F 18; Flortaucipir-F-18
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 06 Oct 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: 210 mg LY3303560 arm.
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.
- 23 Aug 2018 Planned End Date changed from 1 Jun 2020 to 5 Jun 2020.